Hartford Multifactor Developed Markets (ex-US) ETF
RODM - ETF AI Analysis
Top Page
Hartford Multifactor Developed Markets (ex-US) ETF (RODM)
RODM, the Hartford Multifactor Developed Markets (ex-US) ETF, earns a solid overall rating thanks to several high-quality holdings like Novartis, Roche, GSK, and Fairfax Financial, which all show strong financial performance, healthy cash flows, and generally positive technical momentum and earnings call sentiment. Some positions, such as Ericsson and TotalEnergies, add value through attractive valuations and supportive technical trends but face risks from weaker revenue growth, profitability challenges, and external factors like tax environments. The main risk for the ETF is its meaningful exposure to stocks that are showing overbought technical conditions or valuation concerns, which could limit near-term upside.
RODM vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.67B
- Region
- Developed Markets
- Expense Ratio
- 0.29%
- Beta
- 0.46
- Issuer
- Hartford
- Inception Date
- Feb 25, 2015
- Dividend Yield
- 2.83%
- Asset Class
- Equity
- Index Tracked
- Hartford Risk-Optimized Multi Developed Markets Ex-US Index
RODM Summary
RODM is an exchange-traded fund that follows the Hartford Risk-Optimized Multi Developed Markets Ex-US Index, giving you broad exposure to stocks from developed countries outside the United States, such as Japan, the UK, and Canada. It owns a wide mix of companies across many industries, including well-known names like Roche and Novartis, which helps spread your risk and offers international diversification in one investment. This ETF may appeal to investors who want long-term growth and a more globally balanced portfolio. A key risk is that international stock prices can go up and down with global markets and currency changes.
How much will it cost me?
This ETF has an expense ratio of 0.29%, which means you’ll pay about $2.90 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because it uses an actively designed multifactor strategy rather than simple passive tracking.
What would affect this ETF?
RODM could benefit from steady growth in developed markets outside the U.S., especially if global economic conditions improve and sectors like financials, industrials, and health care continue to perform well, supporting its diversified mix of companies such as Roche, Novartis, and Shell. On the downside, rising interest rates, slower growth in Europe or Japan, currency swings, or new regulations affecting energy and large international firms could weigh on returns and add volatility to this broad international ETF.
RODM Top 10 Holdings
RODM leans heavily on big international health care and energy names, with Roche, Novartis, and Astellas Pharma all rising and giving the fund a steady defensive backbone. On the energy side, TotalEnergies and Shell have been strong performers, acting like twin engines pushing returns higher as global energy markets stay firm. Ericsson adds a bit of tech flavor with solid recent momentum, while Canon and GSK are more mixed, occasionally dragging on the fund’s pace. Overall, it’s a diversified, developed-markets ex-US play with a clear tilt toward European and Japanese blue chips.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Telefonaktiebolaget LM Ericsson Class B | 1.02% | $16.93M | SEK 349.38B | 15.98% | 72Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| Astellas Pharma | ― | ― | ― | ― | 69Neutral | |
| TotalEnergies SE | 1.00% | $16.65M | EUR 178.15B | 43.88% | 78Outperform | |
| Novartis AG | 0.99% | $16.43M | CHF 243.98B | 28.90% | 80Outperform | |
| GlaxoSmithKline | 0.92% | $15.23M | $97.86B | 2.55% | 77Outperform | |
| Fairfax Financial Holdings | ― | ― | ― | ― | 81Outperform | |
| Koninklijke Ahold Delhaize N.V. | 0.88% | $14.65M | EUR 30.15B | -1.97% | 62Neutral |
RODM Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RODM, the sentiment is Negative. The current price of 40.88 is below the 20-day moving average (MA) of 41.97, below the 50-day MA of 41.62, and above the 200-day MA of 40.72, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.81 is Neutral, neither overbought nor oversold. The STOCH value of 26.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RODM.
RODM Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $40.89 | $45.00(10.06% Upside) | $1.67B | 0.29% | 66Neutral | |
| $42.66 | $46.97(10.10% Upside) | $6.67B | 0.40% | 69Neutral | |
| $44.85 | $52.90(17.95% Upside) | $5.92B | 0.25% | 65Neutral | |
| $53.96 | $69.01(27.89% Upside) | $4.00B | 0.25% | 71Outperform | |
| $47.66 | $61.46(28.95% Upside) | $3.97B | 0.30% | 69Neutral | |
| $39.84 | $47.58(19.43% Upside) | $3.67B | 0.16% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RODM | Hartford Multifactor Developed Markets (ex-US) ETF | 40.88 | 6.78 | 19.88% | |
| LVHI | Legg Mason International Low Volatility High Dividend ETF | 42.66 | 8.43 | 24.62% | |
| GSIE | Goldman Sachs ActiveBeta International Equity ETF | 44.85 | 5.87 | 15.05% | |
| IDMO | Invesco S&P International Developed Momentum ETF | 53.96 | 3.67 | 7.30% | |
| IMTM | iShares MSCI Intl Momentum Factor ETF | 47.66 | 3.43 | 7.76% | |
| INTF | iShares MSCI Intl Multifactor ETF | 39.84 | 5.49 | 15.98% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
